We have developed an approach to address the ever-growing threat of drug resistant infections using targeted or localized, as opposed to systemic, administration. Our approach is to use a targeted or localized administration as opposed to systemic administration. Our approach affords the opportunity to increase the efficacy and lower the toxicity of antimicrobial agents by:
The products being developed by Armis will be for the treatment and prevention of severe, localized, drug-resistant infections. We will initially focus on the large and unmet needs in colorectal, orthopedic, cardiothoracic and other surgical indications.